Journal of AOAC International
August 13, 2025
Kimberley Foster, Isaac Morrison, S. Daniel et al.
4 citations
Dried, cultivated Psilocybe cubensis fruiting bodies contained an average of 1.14% psilocybin and psilocin by weight, but batch-to-batch variability led to significant differences in projected dosage, especially for amounts of 3 grams or more. The homogenized biomass showed acceptable levels of microbial, mycotoxin, pesticidal, and heavy metal content, with no significant carcinogenic or other health hazards. Encapsulated biomass stably maintained tryptamine content for 11 months. Standardized, safe biomass suitable for human consumption can be achieved under stringent, aseptic conditions, but each batch should be tested for tryptamine content due to observed variability.
Online Journal of Complementary & Alternative Medicine
October 28, 2022
Winston de la Haye
2 citations
Psilocybin, the active compound in psychedelic mushrooms, is gaining renewed attention in psychiatry as a treatment for mental health, building on a history of indigenous healing practices. Although formally identified in 1956, archaeological evidence suggests psilocybin use dates back to at least 6,000 BCE, with depictions in Spanish cave art and documented use among Pre-Columbian, ancient Egyptian, and Greco-Roman cultures for sacred rituals and resolving complex themes. This traditional use fits within Complementary and Alternative Medicine (CAM), offering non-invasive, pleasant therapies that accompany conventional medicine.
SLEEP
May 1, 2025
Denise C. Vidot, Amrit Baral, Bria-Necole Diggs et al.
Among 18-to-35-year-olds in the Herbal Heart Study, 39.5% reported lifetime psychedelic use and 32.8% reported psilocybin use. Overall, 54.5% were satisfied with sleep, 23.0% dissatisfied, and 22.5% neutral, with no differences in sleep satisfaction across the full sample. However, among Hispanic/Latino participants, 33.9% of psychedelic consumers reported sleep dissatisfaction versus 17.2% of non-consumers. Hispanic/Latino psychedelic consumers had 4.4 times higher odds of both sleep dissatisfaction and satisfaction compared to being neutral; psilocybin-alone consumers had 9.2 times higher odds of dissatisfaction. No associations appeared among non-Hispanic White, non-Hispanic Black, or other groups, suggesting a complex link specific to Hispanic/Latino individuals.